Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: SB683699

Sponsor

GlaxoSmithKline